

# Autologous Stem Cell Transplant in other Neuro-Inflammatory diseases

ACTRN12622000530729

---

Status	RECRUITING
Phase	Phase 2
Sponsor	St Vincent's Hospital, Sydney
Enrollment	20 participants

## Plain Language Summary

---

Some neurological conditions — diseases that affect the brain, spinal cord, or nerves — are driven by the immune system attacking the nervous system. When standard treatments such as steroids or other immune-suppressing medications are not working well enough, one option is an autologous haematopoietic stem cell transplant (AHSCT). This procedure uses the patient's own blood stem cells to essentially reset the immune system.

The treatment involves two stages: first, the patient's stem cells are collected from the bloodstream after being stimulated to increase in number. Then, after a course of chemotherapy to clear the existing immune system, the stem cells are returned to the body to rebuild a new, healthier immune system. This study investigates whether this procedure is safe and beneficial for patients with severe, treatment-resistant neuro-inflammatory diseases using a particular combination of chemotherapy drugs.

You may be eligible if you are between 18 and 70 years old, have a severe neuro-inflammatory condition that has not responded to standard therapy, have adequate heart, lung, and kidney function, have no active serious infections, and the transplant has been recommended by a specialist panel as appropriate for your condition.

## Key Eligibility Criteria

---

### Inclusion (21)

- HSCT patients with NID
  - Age 18-65
  - Age 65-70 (may be considered only if HCT-CI<3 and deemed fit both physically and cognitively by at least two investigators)
  - Adequate organ function as measured by:
    - o Cardiac LV Ejection Fraction > 45%
- ... and 16 more (see full listing online)

### Exclusion (6)

- Any patient on the study treatment arm deemed not suitable for transplant by a consensus of HSCT specialists as determined at the HSCT MDT.
  - Any patient unable to understand the purpose and risks of the study or adhere to the post-transplant management including medication adherence and appointment attendance.
  - Patients with a predominately progressive form of disease.
  - Patients where mimics have not been adequately excluded.
  - Patients unable to undergo MRI scans.
- ... and 1 more (see full listing online)

## Locations (1 total)

---

St Vincent's Private Hospital (Darlinghurst) - Darlinghurst, NSW, Australia

<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12622000530729>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [anzctr.org.au](http://anzctr.org.au). Generated by [ClinicalTrialsFinder.org](http://ClinicalTrialsFinder.org).